- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: Glutathione.
Displaying page 2 of 2.
«
Previous
1
2
EudraCT Number: 2008-007748-33 | Sponsor Protocol Number: AIRCo01.12.2008/1 | Start Date*: 2010-04-09 | |||||||||||
Sponsor Name:Foreest Medical School | |||||||||||||
Full Title: Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients | |||||||||||||
Medical condition: Insulin resistance in colon cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004776-56 | Sponsor Protocol Number: AT1-2017 | Start Date*: 2019-03-06 |
Sponsor Name:Arctic Therapeutics ehf | ||
Full Title: Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study | ||
Medical condition: Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IS (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-005050-11 | Sponsor Protocol Number: SeMMIviD | Start Date*: 2019-03-08 | |||||||||||
Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI | |||||||||||||
Full Title: Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial | |||||||||||||
Medical condition: Graves' disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001294-84 | Sponsor Protocol Number: OPBGC&RS2011-004_CA2012 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:EDISON PHARMACEUTICALS INC. | |||||||||||||
Full Title: Prospective open label trial to evaluate the maintenance of the efficacy and the long term safety of EPI-743 in children with Leigh Disease | |||||||||||||
Medical condition: Leigh Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002920-33 | Sponsor Protocol Number: CLI00076 | Start Date*: 2012-12-10 |
Sponsor Name:CERUS CORPORATION | ||
Full Title: A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion | ||
Medical condition: Subjects with Thalassemia Major Requiring Chronic RBC Transfusion | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005939-10 | Sponsor Protocol Number: V232-055 | Start Date*: 2006-05-15 | |||||||||||
Sponsor Name:Merck & Co. Inc. | |||||||||||||
Full Title: A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine | |||||||||||||
Medical condition: Hepatitis B ICD10 classification code : Hepatitis Viral- Type B (ICD10- B16) MedDRA classification code : Infections and Infestations – Viral Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002964-15 | Sponsor Protocol Number: STH19102 | Start Date*: 2016-12-06 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals | |||||||||||||
Full Title: The Effect of Selenium Supplementation on Musculoskeletal Health in Older Women Double-blind, randomised, placebo-controlled trial | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001074-26 | Sponsor Protocol Number: S-CPR2011 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin | |||||||||||||
Full Title: Effect of High Dose Selenium on Inflammation and Neurological Outcome after Cardiac Arrest: A randomized, double blind placebo controlled phase 2a study | |||||||||||||
Medical condition: Cardiac Arrest with successful resuscitation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001786-10 | Sponsor Protocol Number: EPI589-15-002 | Start Date*: 2016-01-18 | ||||||||||||||||
Sponsor Name:BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.) | ||||||||||||||||||
Full Title: A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects | ||||||||||||||||||
Medical condition: Parkinson’s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001990-32 | Sponsor Protocol Number: NOV002-C301 | Start Date*: 2006-11-22 | |||||||||||
Sponsor Name:NOVELOS THERAPEUTICS INC. | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NS... | |||||||||||||
Medical condition: Patients with advanced NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001573-28 | Sponsor Protocol Number: Uni-Koeln-320 | Start Date*: 2007-11-26 |
Sponsor Name:Universität zu Köln | ||
Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. | ||
Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004344-19 | Sponsor Protocol Number: LA48-0215 | Start Date*: 2016-03-31 | |||||||||||
Sponsor Name:ApoPharma | |||||||||||||
Full Title: A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson’s Disease | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003265-19 | Sponsor Protocol Number: PD0053 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkins... | |||||||||||||
Medical condition: Early-stage Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) PL (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000215-32 | Sponsor Protocol Number: Pycno2015-14 | Start Date*: 2016-10-04 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Antwerp | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD): A randomized, double blind, placebo and active product controlled multicenter trial. | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Attention-deficit hyperactivity disorder (ADHD) | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
«
Previous
1
2
